About Aartia Kem Science
Aartia Kem Science is a Healthcare company based in Mumbai (India) founded in 2017. It offers API development, manufacturing, regulatory support, and quality pharmaceutical products. It operates on a B2B model. Aartia Kem Science offers products and services including API Development, FDF Formulation, and DMF Documentation. Its focus areas include Pharmaceuticals, API Manufacturing, Generic API Development and Regulatory Services. Its legal entity in India is Dongbang Ftl India Private Limited (U24306MH2020FTC337604). Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Aartia Kem Science specializes in vertically integrated services from API development to FDF formulation and manufacturing, based in Mumbai, India. They focus on innovation in generic API development, ensure regulatory compliance with standards like USFDA and EMA, and serve thousands of customers worldwide. The company emphasizes quality control, timely deliveries, and customer satisfaction through a team of professionals.
- Headquarters Mumbai, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aartiakem.com
- Legal Name Dongbang Ftl India Private Limited
- Date of Incorporation 12 Feb, 2020
- Jurisdiction Borivli East Mumbai, Maharashtra, India
- Net Loss-₹9.6 Lakh
FY 2022 · -223199% margin
- EBITDA-₹8.6 Lakh
FY 2022 · -199829% margin
Associated legal entities of Aartia Kem Science
Aartia Kem Science operates through Dongbang Ftl India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dongbang Ftl India Private Limited CIN U24306MH2020FTC337604 | Active | 12 Feb 2020 | Mumbai, Maharashtra | ₹0.0 Cr | 3 | View details |
Products & Services of Aartia Kem Science
Aartia Kem Science offers a comprehensive portfolio of products and services, including API Development, FDF Formulation, and DMF Documentation.
Services for developing active pharmaceutical ingredients with quality assurance.
Manufacturing of finished dosage forms for pharmaceutical use.
Preparation of documentation for drug master files compliance.
Board of directors of Dongbang Ftl India Private Limited (Aartia Kem Science)
Dongbang Ftl India Private Limited is the primary company behind Aartia Kem Science. The board of Dongbang Ftl India Private Limited currently have 2 directors; the longest-serving is Jongyoon Kim, appointed in 2020. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jongyoon Kim DIN 08697759 | Director | 12 Feb 2020 | 6 yrs 8 mo | Dongbang Ftl India Private Limited |
| Hun Suk Chung DIN 08697758 | CEO | 13 Mar 2020 | 6 yrs 8 mo | Dongbang Ftl India Private Limited |
Financials of Aartia Kem Science
Figures of Dongbang Ftl India Private Limited, the primary company behind Aartia Kem Science, for FY 2022. Net loss was -₹9.6 Lakh (-223199% margin). EBITDA was -₹8.6 Lakh (-199829% margin).
- -₹9.6 LakhNet loss · -223199% margin
- -₹8.6 LakhEBITDA · -199829% margin
- ₹38 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Dongbang Ftl India Private Limited are on its company page.
Detailed financial statements for Aartia Kem Science
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Aartia Kem Science
Aartia Kem Science has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Aartia Kem Science
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aartia Kem Science
Aartia Kem Science was founded in 2017.
Aartia Kem Science is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Annual revenue of Aartia Kem Science is $5.19 as on Mar 31, 2022.
Aartia Kem Science specializes in vertically integrated services from API development to FDF formulation and manufacturing, based in Mumbai, India. They focus on innovation in generic API development, ensure regulatory compliance with standards like USFDA and EMA, and serve thousands of customers worldwide. The company emphasizes quality control, timely deliveries, and customer satisfaction through a team of professionals.
Aartia Kem Science's top competitors include Laurus Labs, Symbiotec and SeQuent.
Aartia Kem Science offers API Development, FDF Formulation, and DMF Documentation.
Aartia Kem Science operates through Dongbang Ftl India Private Limited.
The legal entities of Aartia Kem Science currently have 2 directors, including Hun Suk Chung, Jongyoon Kim.